Charles River, Valo Health announce strategic partnership

By The Science Advisory Board staff writers

January 20, 2022 -- Charles River Laboratories and Valo Health have formed a multiyear strategic partnership to offer a transformative, artificial intelligence (AI)-enabled drug discovery and development platform.

The collaboration intends to create and deliver offerings that produce preclinical assets with key performance characteristics optimized for client preferences, the companies said. The partnership's combined offerings will utilize Valo's Opal platform for small molecule development, which leverages a "closed-loop," in-silico experimental platform that rapidly iterates using program data to identify novel compounds, and Charles River's capabilities in discovery optimization -- including medicinal chemistry, absorption, distribution, metabolism and excretion, biology, pharmacology, and, ultimately, safety testing and investigational new drug submission.

The combined offering will be launched in the first half of 2022 and will be available exclusively from Charles River.

No financial details were disclosed.

Copyright © 2022
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here